Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

I-Mab(I-Mab) is a biopharmaceutical company. It develops transformational medicines focused on the therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong, and the US. I-Mab is headquartered in Shanghai, China.

Headquarters China

Address Willow House, Floor 4, Shanghai, 200124


Telephone 86 21 60578000

No of Employees 378

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange IMAB (NASD)

Revenue (2021) $13.6M 5042.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 132.4% (2021 vs 2020)

Market Cap* $949.6M

Net Profit Margin (2020) XXX 100.6% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for I-Mab’s relevant decision makers and contact details.

70+

Catalyst Calendar

Proactively evaluate I-Mab’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Pipeline Drugs

Identify which of I-Mab’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Clinical Trials

Determine I-Mab go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
TJ202:
(Felzartamab): Multiple Myeloma
TJ101 (eftansomatropin):
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company entered into a strategic collaboration with Ferring Pharmaceuticals to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
2022 Official Trials/Tests In May, the company announced the completion of patient enrollment in a Phase 3 clinical trial to treat pediatric growth hormone deficiency in China.
2022 Others In April, the company rating was upgraded by Zacks Investment Research from a sell rating to a hold rating.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters I-Mab CStone Pharmaceuticals Co Ltd Akeso Inc JW Cayman Therapeutics Co Ltd CARsgen Therapeutics Ltd
Headquarters China China China China China
City Shanghai Shanghai Zhongshan Shanghai Shanghai
State/Province Shanghai Shanghai Guangdong Shanghai Shanghai
No. of Employees 378 263 1,865 534 573
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jingwu Zhang Zang Founder; Chairman; Chief Executive Officer - Acting Executive Board 2021 66
John Long Chief Financial Officer; Director Executive Board 2021 50
Richard Yeh Director; Chief Operating Officer Executive Board 2022 54
Andrew Zhu President; Director Executive Board 2021 62
Zheru Zhang Director; President Executive Board 2017 59
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer